yingweiwo

c-Kit

c-Kit

c-Kit (Mast/stem cell growth factor receptor, SCFR or CD117) is a proteinthat in humans is encoded by the KIT gene.An essential cell surface marker for identifying specific kinds of hematopoietic (blood) progenitors in the bone marrow is called c-Kit (CD117). In addition to other cell types, hematopoietic stem cells express the cytokine receptor c-Kit on their surface. Some types of cancer may be linked to altered forms of this receptor. Stem cell factor is bound by the type III receptor tyrosine kinase known as c-Kit. To activate its intrinsic tyrosine kinase activity, c-Kit forms an adimer with stem cell factor (SCF). This adimer then phosphorylates and activates signal transduction molecules that spread the signal throughout the cell. Cell survival, division, and proliferation are affected by c-Kit signaling.

c-Kit related products

Structure Cat No. Product Name CAS No. Product Description
Anti-Mouse CD117 Antibody V77254 Anti-Mouse CD117 Antibody Anti-Mouse CD117 Antibody is an IgG2b antibody inhibitor against mouse CD117.
AZD3229 V3474 AZD3229 2248003-60-1 AZD3229 (AZD-3229) is a novel, potent, pan-KIT mutantinhibitor with anticancer activity.
AZD3229 Tosylate V4154 AZD3229 Tosylate 2248003-71-4 AZD3229 Tosylate, the tosylate salt ofAZD-3229,is a novel, potent, pan-KIT mutantinhibitor with antitumor activity.
Bezuclastinib (CGT9486; PLX 9486) V69291 Bezuclastinib (CGT9486; PLX 9486) 1616385-51-3 Bezuclastinib (CGT9486; PLX 9486) is a potent inhibitor of c-kit and c-kit D816V, 0.0001
c-Kit 抑制剂ISCK03 V22674 ISCK03 945526-43-2 ISCK03 is a potent c-kit inhibitor.
DCC-2618 HCl V3757 DCC-2618 HCl Ripretinib HCl (DCC2618; DCC-2618; Qinlock), the hydrochloride salt of DCC-2618, is an orally bioactive pan KIT and PDGFRA inhibitor approved in 2020 for the treatment of adults with advanced gastrointestinal stromal tumor.
Elenestinib (BLU-263) V69295 Elenestinib (BLU-263) 2505078-08-8 Elenestinib (BLU-263) is a potent orally bioactive tyrosine kinase inhibitor.
Elenestinib phosphate (BLU-263 phosphate) V69296 Elenestinib phosphate (BLU-263 phosphate) 2832013-93-9 Elenestinib phosphate (BLU-263 phosphate) is a potent orally bioactive tyrosine kinase inhibitor.
Labuxtinib V69290 Labuxtinib 1426449-01-5 Labuxtinib is a c-kit tyrosine kinase inhibitor (TKI).
SU14813 V15392 SU14813 627908-92-3 SU14813 is a novel, orally bioavailable, multi-targeted tyrosine kinase inhibitor (TKI) withIC50s of 50, 2, 4, 15 nM forVEGFR2,VEGFR1,PDGFRβandKIT, respectively.
Tyrphostin AG 1288 V88006 Tyrphostin AG 1288 116313-73-6 Tyrphostin AG 1288 is a potent tyrosine kinase inhibitor.
VEGFR-IN-1 V69294 VEGFR-IN-1 269390-69-4 VEGFR-IN-1 (compound 3) is a potent angiogenesis inhibitor (antagonist) with IC50 of 0.02, 0.18, 0.24, 7.3, and 7 for KDR, Flt-1, c-Kit, EGF-R, and c-Src, respectively.
喹氟拉辛 V13471 Quarfloxin 865311-47-3 Quarfloxin (Quarfloxacin; CX-3543) is a novel and potent fluoroquinolone analoguewith anticancer activity.
培西达替尼 V0630 Pexidartinib (PLX3397; Turalio; CML261; FP113) 1029044-16-3 Pexidartinib (formerly PLX-3397; CML-261;FP-113; trade name Turalio) is an orally bioavailable and multi-targeted RTK (receptor tyrosine kinase) inhibitor of CSF-1R, Kit, and Flt3 with potential antineoplastic activity.
甲磺酸伊马替尼 V0572 Imatinib Mesylate (STI571; Gleevec; Glivec) 220127-57-1 Imatinib Mesylate (also known as STI571 mesylate; trade names: Gleevec or Glivec), the mesylate salt of imatinib, is an orally bioavailable,potent,multi-kinase inhibitor of v-Abl, c-Kit and PDGFR with potential antitumor activity.
达沙替尼一水合物 V0631 Dasatinib Monohydrate (BMS354825; Sprycel) 863127-77-9 Dasatinib (formerly BMS-354825; trade name Sprycel), an approved anticancer drug, is an orally bioavailable and multi-targeted kinase inhibitorof Abl, Src and c-Kit with potential anticancer activity.
阿伐普替尼 V2886 Avapritinib 1703793-34-3 Avapritinib (formerly known as BLU-285; trade name Ayvakit) is an oral, potent and selective small molecule inhibitor of PDGFRα D842V and KIT Exon 17 mutants (IC50=0.5 nM) with anticancer activity.
Contact Us